Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Escitalopram - Lundbeck A/S

Drug Profile

Escitalopram - Lundbeck A/S

Alternative Names: Cipralex; Entact; Escitalopram Oxalate; Lexapro; LU-26054; MLD-55; S-citalopram; Seroplex; Sipralex; Sipralexa

Latest Information Update: 22 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer AbbVie; Forest Laboratories; Lundbeck A/S; Mochida Pharmaceutical
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Benzofurans; Fluorobenzenes; Nitriles; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia

Most Recent Events

  • 22 Nov 2022 Escitalopram is still in phase-III trials for Major depressive disorder (In adolescents, In children) in Japan (PO) (Mochida Pharmaceutical pipeline, November 2022)
  • 08 Mar 2022 No development reported - Phase-III for Major depressive disorder (In adolescents, In children) in Japan (PO)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top